Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-d-glucose positron emission tomography and computed tomography

Clinical Lung Cancer

Volumn 14, Issue 3, 2013, Pages 230-237

  Novello, Silvia ^a   Vavalà, Tiziana ^a   Levra, Matteo Giaj ^a   Solitro, Federica ^a   Pelosi, Ettore ^b   Veltri, Andrea ^a   Scagliotti, Giorgio V ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Via Onorato Vigliani   (Italy)

Author keywords

Antiangiogenic therapy; First line treatment; Objective response; Positron emission tomography (PET); Sorafenib

Indexed keywords

CARBOPLATIN; FLUORODEOXYGLUCOSE F 18; PACLITAXEL; PLACEBO; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER TOMOGRAPHY SCANNER; CONTROLLED STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; METABOLISM; MULTIDETECTOR COMPUTED TOMOGRAPHY; OVERALL SURVIVAL; PET SCANNER; PHASE 3 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TREATMENT DURATION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PACLITAXEL; PHENYLUREA COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS;

EID: 84879920465     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2012.10.004     Document Type: Article

References (57)

1. GLOBOCAN 2008 Cancer Fact Sheet - Lung Cancer http://globocan.iarc.fr/ factsheets/cancers/lung.asp Accessed: December 12, 2012
2. R. Siegel, D. Naishadham, A. Jemal Cancer statistics CA Cancer J Clin 2011 2012 10 29
3. Surveillance, Epidemiology and End Results: SEER Stat Fact Sheets: Lung and Bronchus. Available at Accessed: December 12, 2012
4. C.G. Azzoli, S. Baker Jr, S. Temin American Society of Clinical Oncology Clinical Practice guideline update on chemotherapy for stage IV non-small-cell lung cancer J Clin Oncol 27 2009 6251 6626
5. D. Hellwig, T.P. Graeter, D. Ukena Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma J Thorac Cardiovasc Surg 128 2004 892 899
6. K. Spaepen, S. Stroobants, P. Dupont Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19 2001 414 419
7. M. Schulte, D. Brecht-Krauss, M. Werner Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET J Nucl Med 40 1999 1637 1643
8. R.L. Wahl, K. Zasadny, M. Helvie Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation J Clin Oncol 11 1993 2101 2111
9. T. Jansson, J.E. Westlin, H. Ahlström Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 13 1995 1470 1477
10. P. Bassa, E.E. Kim, T. Inoue Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer J Nucl Med 37 1996 931 938
11. M. Schelling, N. Avril, J. Nährig Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer J Clin Oncol 18 2000 1689 1695
12. I.C. Smith, A.E. Welch, A.W. Hutcheon Positron emission tomography using [(18)F]-fluorodeoxy-d-glucose to predict the pathologic response of breast cancer to primary chemotherapy J Clin Oncol 18 2000 1676 1688
13. J.F. Vansteenkiste, S.G. Stroobants, P.R. De Leyn Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study The Leuven Lung Cancer Group Ann Oncol 9 1998 1193 1198
14. C.J. Hoekstra, S.G. Stroobants, E.F. Smit Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer J Clin Oncol 23 2005 8362 8370
15. W.A. Weber, V. Petersen, B. Schmidt Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use J Clin Oncol 21 2003 2651 2657
16. M.E. Phelps Positron emission tomography provides molecular imaging of biological processes Proc Natl Acad Sci U S A 97 2000 9226 9233
17. H.R. Herschman Molecular imaging: looking at problems, seeing solutions Science 302 2003 605 608
18. T. Massoud, S. Gambhir Molecular imaging in living subjects: seeing fundamental biological processes in a new light Genes Dev 17 2003 545 580
19. W.A. Weber, S.I. Ziegler, R. Thödtmann Reproducibility of metabolic measurements in malignant tumors using FDG PET J Nucl Med 40 1999 1771 1777
20. UICC, International Union Against Cancer TNM classification of malignant tumors 6th ed. 2002 Wiley-Liss New York
21. American Joint Committee on Cancer AJCC Cancer Staging Manual 6th ed. 2002 Springer New York
22. L.T. Tanoue, F.C. Detterbeck New TNM classification for non-small-cell lung cancer Expert Rev Anticancer Ther 9 2009 413 423
23. G.V. Scagliotti, S. Novello, J. von Pawel Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer J Clin Oncol 28 2010 1835 1842
24. P. Therasse, S.G. Arbuck, E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Insitute 92 2000 205 216
25. H. Young, R. Baum, U. Cremerius Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur J Cancer 35 1999 1173 1182
26. R.L. Wahl, H. Jacene, Y. Kasamon From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors J Nucl Med 50 suppl 1 2009 122s 150s
27. N.H. Hanna, J. Von Pawel, M. Reck Carboplatin/paclitaxel with/without sorafenib in chemonaive patients with stage IIIB-IV non-small cell lung cancer: interim analysis (IA) results from a randomized phase III trial (escape) J Thorac Oncol 3 suppl 4 2008 s268 abstract 14
28. M. Findlay, H. Young, D. Cunningham Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil J Clin Oncol 14 1996 700 708
29. M. Thomas, C. Rübe, M. Semik Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer J Clin Oncol 17 1999 1185 1193
30. Y. Ichiya, Y. Kuwabara, M. Sasaki A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma Ann Nucl Med 10 1996 193 200
31. S.M. Eschmann, G. Friedel, F. Paulsen Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer Lung Cancer 55 2007 165 171
32. C. Nahmias, W.T. Hanna, L.M. Wahl Time course of early response to chemotherapy in non-small cell lung cancer patients with 18F-FDG PET/CT J Nucl Med 48 2007 744 751
33. L.F. de Geus-Oei, H.F. van der Heijden, E.P. Visser Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer J Nucl Med 48 2007 1592 1597
34. K.S. Albain, V.W. Rusch, J.J. Crowley Long-term survival after concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery in bulky, stages IIIA (N2) and IIIB non-small cell lung cancer: 6-year outcomes from Southwest Oncology Group Study 8805 Proc Am Soc Clin Oncol 18 1999 467
35. M.P. Mac Manus, R.J. Hicks, J.P. Matthews Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer J Clin Oncol 121 2003 1285 1292
36. T.W. Rice, D.J. Adelstein, J.P. Ciezki Short-course induction chemoradiotherapy with paclitaxel for stage III non-small-cell lung cancer Ann Thorac Surg 66 1998 1909 1914
37. K.M.W. Pisters, M.G. Kris, R.J. Gralla Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small cell lung cancer combined modality trials J Clin Oncol 17 1999 1185 1193
38. J. Vansteenkiste, B.M. Fischer, C. Dooms Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review Lancet Oncol 5 2004 531 540
39. M.P. Mac Manus, R.J. Hicks, J.P. Matthews Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure Lung Cancer 49 2005 95 108
40. N.C. Choi, A.J. Fischman, A. Niemierko Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer Int J Radiat Oncol Biol Phys 54 2002 1024 1035
41. R.J. Cerfolio, A.S. Bryant, T.S. Winokur Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer Ann Thorac Surg 78 2004 1903 1909
42. C. Pöttgen, S. Levegrün, D. Theegarten Value of 18F-fluoro-2-deoxy-d-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy Clin Cancer Res 12 2006 97 106
43. Y. Yamamoto, Y. Nishiyama, T. Monden Correlation of FDG-PET findings with histopathology in the assessment of response to induction chemoradiotherapy in non-small cell lung cancer Eur J Nucl Med Mol Imaging 33 2006 140 147
44. A.J. de Langen, V. van den Boogaart, M. Lubberink Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI J Nucl Med 52 2011 48 55
45. H.A. Wieder, B.L. Brücher, F. Zimmermann Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment J Clin Oncol 22 2004 900 908
46. D.A. Elson, H.E. Ryan, J.W. Snow Coordinate up-regulation of hypoxia inducible factor (HIF)-1alpha and HIF-1 target genes during multi-stage epidermal carcinogenesis and wound healing Cancer Res 60 2000 6189 6195
47. P.W. Hruz, M.M. Mueckler Structural analysis of the GLUT1 facilitative glucose transporter (review) Mol Membr Biol 18 2001 183 193
48. M.M. Vleugel, A.E. Greijer, A. Shvarts Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer J Clin Pathol 58 2005 172 177
49. J.A. Thie Understanding the standardized uptake value, its methods, and implications for usage J Nucl Med 45 2004 1431 1434
50. L. Geworski, B.O. Knoop, M.L. de Cabrejas Recovery correction for quantitation in emission tomography: a feasibility study Eur J Nucl Med 27 2000 161 169
51. K. Kaira, M. Endo, M. Abe Biologic correlation of 2-[18F]-fluoro-2-deoxy- d-glucose uptake on positron emission tomography in thymic epithelial tumors J Clin Oncol 28 2010 3746 3753
52. E. Pelosi, A. Billè, A. Skanjeti Prognostic role of the PET parameter maximum standardized uptake value in non small cell lung cancer: analysis in tumour of diameter ≥ and <25 mm Q J Nucl Med Mol Imaging 55 2011 72 80
53. S. Kim, J.E. Kim, K. Kim Standard chemotherapy strategy versus changing chemotherapy strategy as to FDG-PET response after first cycle of standard chemotherapy for advanced NSCLC J Clin Oncol 29 suppl 2011 abstract 7558 www.asco.org Accessed December 12, 2012
54. 18fdg-PET J Clin Oncol 28 suppl 2010 abstract 7038 www.asco.org Accessed: December 12, 2012
55. B. Zhao, L.H. Schwartz, S.M. Larson Imaging surrogates of tumor response to therapy: anatomic and functional biomarkers J Nucl Med 50 2009 239 249
56. M. Scheffler, T. Zander, L. Nogova [18F]fluoro-L-thymidine (FLT) uptake in baseline positron emission tomography (PET) as a prognostic marker in patients with advanced non-small cell lung cancer (NSCLC) treated first-line with erlotinib J Clin Oncol 29 suppl 2011 abstract 7591 www.asco.org Accessed: December 12, 2012
57. Y. Ohno, H. Koyama, T. Yoshikawa Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy AJR Am J Roentgenol 198 2012 75 82